关于埃博拉试验性治疗的伦理思考

Ethical Consideration on Experimental Treatment of Ebola Virus Disease

国外埃博拉试验性药物目前主要是TKM-Ebola、ZMapp、法匹拉韦等。中国的疫苗也已进入临床试验。而将疫苗提前用于感染患者,带来可能益处的同时伴随风险,引发了诸多医学伦理学争议,如能否绕过常规的临床试验阶段,直接将试验性药物用于埃博拉患者?如何分配有限的试验性药物,灾难面前,其他国家应当给疫区更多的援助吗?

Foreign Ebola experimental drug are mainly TKM - Ebola, ZMapp, favipiravir, and vaccines are developing tensely. Vaccines of our country have entered clinical trials. Some experiments were given to the infec- ted patients in advance, which might not only bring the patients with benefits, but also with risks, thus raised lots of medical ethical disputes. For example, Shall we directly give the experimental drug to Ebola patients bypass the routine clinical trial stage？ How to allocate the limited experimental drug？ In front of the disaster, should other countries give more aid to affected areas？